Related Experiment Videos
[Effects of loperamide on fecal electrolyte excretion in acute diarrhea in infants]
J Ghisolfi1, C Baudoin, J P Charlet
1Service de Médecine Infantile D, CHR Purpan, Toulouse.
Insights
Loperamide (Imodium) did not significantly alter fecal sodium or potassium excretion in infants with acute diarrhea. The drug did not reduce stool frequency or speed recovery compared to placebo.
Area of Science:
- Pediatric Gastroenterology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Acute diarrhea is a common pediatric illness, often leading to electrolyte imbalances.
- Loperamide is an antidiarrheal agent, but its effect on electrolyte excretion in infants requires clarification.
- Understanding electrolyte changes is crucial for managing dehydration in pediatric diarrhea.
Purpose of the Study:
- To investigate the impact of loperamide (Imodium) on fecal electrolyte (sodium and potassium) excretion in infants with acute diarrhea.
- To compare the effects of loperamide versus placebo on stool output, electrolyte concentrations, and recovery time.
Main Methods:
- A double-blind study involving 63 infants (1-32 months) with acute diarrhea.
- Infants received oral rehydration and either loperamide (0.16-0.20 mg/kg/24h) or placebo every 8 hours for at least 48 hours.
- Fecal sodium (Na+) and potassium (K+) concentrations were measured before and after treatment.
Main Results:
- Loperamide treatment showed a non-significant decrease in fecal sodium concentration compared to pre-treatment values.
- A significant difference in fecal sodium was observed between groups (p<1%), primarily due to increased sodium in the placebo group.
- Loperamide did not significantly reduce stool frequency, alter fecal potassium, or accelerate recovery compared to placebo.
Conclusions:
- Loperamide does not significantly affect fecal sodium and potassium excretion in infants with acute diarrhea.
- The observed changes in fecal sodium were mainly influenced by the placebo group's increased output, not a reduction by loperamide.
- Loperamide's efficacy in reducing stool frequency or speeding recovery in this infant population was not demonstrated in this study.
Abstract:
The effect of loperamide (Imodium) on fecal excretion of electrolytes was studied using a double-blind protocol in 63 infants aged 1 to 32 months, presenting with acute diarrhea. The etiology of these infections was due to virus (n = 9), E. coli (n = 4), Salmonella (n = 4), Shigella (n = 2) or was of undetermined origin (n = 34). The therapeutic protocol was the same for all the infants: ad libitum oral rehydration, with no drug being administered except for Imodium at an average dose of 20 to 25 drops/kg/24 h (0.16 to 0.20 mg/kg/24 h), given every 8 hours for at least 48 hours. Stool Na+ and K+ concentrations were determined in samples taken before and after the double-blind trial. In patients receiving loperamide, we observed a non-significant decrease in fecal Na+ concentration as compared with values before treatment. Comparison of the two groups of infants, one receiving Imodium, the other a placebo, showed a significant difference (p less than 1%) in fecal sodium concentration, due rather to an increase in stool Na+ in the placebo group than to a decrease in the group treated with Imodium. Moreover, the use of loperamide, compared with the placebo, did not result in a significant decrease in the number of stools, modified fecal K+ values, or more rapid recovery from the diarrheal syndrome.